Clinical Trial Update: Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating activated recombinant human factor VII for bleeding management during cardiopulmonary bypass in pediatric congenital heart disease has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Bleeding Disorder
• Congenital Heart Disease

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass | Phase 3 | Status: COMPLETED